The NYRx Education & Outreach team shared the following update.
Effective November 6, 2025, Rybelsus 3mg will be subject to the following clinical criteria:
- Prescriptions will be limited to a duration of 30 days, with no refills.
- Use for glycemic control will not be covered. System updates will be made to ensure alignment of coverage and criteria. Any claims that do not meet the criteria may be impacted and rejected at the pharmacy.
Any claims that do not meet criteria may be impacted and reject at the pharmacy.
The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 am to 5:00 pm ET, Monday through Friday, excluding holidays.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.
For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.
For more information, contact NACDS’ Mary Staples at 817-442-1155.